Search
Now showing items 1-5 of 5
The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinibresistant chronic myeloid leukemia cells
(Taylor & Francis, 2013-07)
In chronic myeloid leukemia (CML), epigenetic modifications such as promoter hypermethylation and inactive histone modification are known mechanisms of drug resistance. In our study, we investigated the roles of promoter ...
Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer
(Elsevier, 2014-08)
Background and Aims: Quercitrin (QR; quercetin-3-O-rhamnoside) has been used previously as an antibacterial agent and has been shown to inhibit the oxidation of low-density lipoproteins and prevent an allergic reaction. ...
Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells
(Elsevier, 2010-04)
Objectives: To investigate the effects of a strong proteasome inhibitor, bortezomib alone or in combination with radiotherapy on androgen-independent DU145 human prostate cancer cells. Proteasomes play important roles in ...
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A
(American Society of Hematology, 2011-06)
The mechanisms by which sphingosine kinase-1 (SK-1)/sphingosine 1-phosphate (S1P) activation contributes to imatinib resistance in chronic myeloid leukemia (CML) are unknown. We show herein that increased SK-1/S1P enhances ...
Multidrug resistance in chronic myeloid leukemia
(TÜBİTAK, 2014)
Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-positive (Ph+) myeloid cells. Ph+ cells occur via a reciprocal translocation between the long arms of chromosomes 9 and 22 ...
